Techniques and Protocols for Dispersing Nanoparticle Powders in Aqueous Media—is there a Rationale for Harmonization?

<div><p>Selecting appropriate ways of bringing engineered nanoparticles (ENP) into aqueous dispersion is a main obstacle for testing, and thus for understanding and evaluating, their potential adverse effects to the environment and human health. Using different methods to prepare (stock) dispersions of the same ENP may be a source of variation in the toxicity measured. Harmonization and standardization of dispersion methods applied in mammalian and ecotoxicity testing are needed to ensure a comparable data quality and to minimize test artifacts produced by modifications of ENP during the dispersion preparation process. Such harmonization and standardization will also enhance comparability among tests, labs, and studies on different types of ENP. The scope of this review was to critically discuss the essential parameters in dispersion protocols for ENP. The parameters are identified from individual scientific studies and from consensus reached in larger scale research projects and international organizations. A step-wise approach is proposed to develop tailored dispersion protocols for ecotoxicological and mammalian toxicological testing of ENP. The recommendations of this analysis may serve as a guide to researchers, companies, and regulators when selecting, developing, and evaluating the appropriateness of dispersion methods applied in mammalian and ecotoxicity testing. However, additional experimentation is needed to further document the protocol parameters and investigate to what extent different stock dispersion methods affect ecotoxicological and mammalian toxicological responses of ENP.</p></div

Interlaboratory comparison study of the Colony Forming Efficiency assay for assessing cytotoxicity of nanomaterials

Nanotechnology has gained importance in the past years as it provides opportunities for industrial growth and innovation. However, the increasing use of manufactured nanomaterials (NMs) in a number of commercial applications and consumer products raises also safety concerns and questions regarding potential unintended risks to humans and the environment. Since several years the European Commission’s Joint Research Centre (JRC) is putting effort in the development, optimisation and harmonisation of in vitro test methods suitable for screening and hazard assessment of NMs. Work is done in collaboration with international partners, in particular the Organisation for Economic Co-operation and Development (OECD). This report presents the results from an interlaboratory comparison study of the in vitro Colony Forming Efficiency (CFE) cytotoxicity assay performed in the frame of OECD's Working Party of Manufactured Nanomaterials (WPMN). Twelve laboratories from European Commission, France, Italy, Japan, Poland, Republic of Korea, South Africa and Switzerland participated in the study coordinated by JRC. The results show that the CFE assay is a suitable and robust in vitro method to assess cytotoxicity of NMs. The assay protocol is well defined and is easily and reliably transferable to other laboratories. The results obtained show good intra and interlaboratory reproducibility of the assay for both the positive control and the tested nanomaterials. In conclusion the CFE assay can be recommended as a building block of an in vitro testing battery for NMs toxicity assessment. It could be used as a first choice method to define dose-effect relationships for other in vitro assays.JRC.I.4-Nanobioscience

Synthetic Amorphous Silicon Dioxide (NM-200, NM-201, NM-202, NM-203, NM-204): Characterisation and Physico-Chemical Properties

The European Commission's Joint Research Centre (JRC) provides scientific support to European Union policy including nanotechnology. Within this context, the JRC launched, in February 2011, a repository for Representative Test Materials (RTMs), based on preparatory work started in 2008. It supports both EU and international research projects, and especially the OECD Working Party on Manufactured Nanomaterials (WPMN). The WPMN leads an exploratory testing programme "Testing a Representative set of Manufactured Nanomaterials" for the development and collection of data on characterisation, toxicological and ecotoxicological properties, as well as risk assessment and safety evaluation of nanomaterials. The purpose is to understand the applicability of the OECD Test Guidelines for the testing of nanomaterials as well as end-points relevant for such materials. The Repository responds to a need for nanosafety research purposes: availability of nanomaterial from a single production batch to enhance the comparability of results between different research laboratories and projects. The availability of representative nanomaterials to the international scientific community furthermore enhances and enables development of safe materials and products. The present report presents the physico-chemical characterisation of the synthetic amorphous silicon dioxide (SiO2, SAS) from the JRC repository: NM-200, NM-201, NM-202, NM-203 and NM-204. NM-200 was selected as principal material for the OECD test programme "Testing a representative set of manufactured nanomaterials". NM-200, NM-201 and NM-204 (precipitated SAS) are produced via the precipitation process, whereas NM-202 and NM-203 (fumed or pyrogenic SAS) are produced via a high temperature process. Each of these NMs originates from one respective batch of commercially manufactured SAS. They are nanostructured, i.e. they consist of aggregated primary particles. The SAS NMs may be used as a representative material in the measurement and testing with regard to hazard identification, risk and exposure assessment studies. The results for more than 15 endpoints are addressed in the present report, including physical-chemical properties, such as size and size distribution, crystallite size and electron microscopy images. Sample and test item preparation procedures are addressed. The results are based on studies by several European laboratories participating to the NANOGENOTOX Joint Action, as well as the JRC.JRC.I.4-Nanobioscience

Titanium Dioxide, NM-100, NM-101, NM-102, NM-103, NM-104, NM-105: Characterisation and Physico-Chemical Properties

The European Commission's Joint Research Centre (JRC) provides scientific support to European Union policy including nanotechnology. Within this context, the JRC launched, in February 2011, a repository for Representative Test Materials (RTMs), based on preparatory work started in 2008. It supports both EU and international research projects, and especially the OECD Working Party on Manufactured Nanomaterials (WPMN). The WPMN leads an exploratory testing programme "Testing a Representative set of Manufactured Nanomaterials" for the development and collection of data on characterisation, toxicological and ecotoxicological properties, as well as risk assessment and safety evaluation of nanomaterials. The purpose is to understand the applicability of the OECD Test Guidelines for the testing of nanomaterials as well as end-points relevant for such materials. The Repository responds to a need for nanosafety research purposes: availability of nanomaterial from a single production batch to enhance the comparability of results between different research laboratories and projects. The availability of representative nanomaterials to the international scientific community furthermore enhances and enables development of safe materials and products. The present report presents the physico-chemical characterisation of the Titanium dioxide series from the JRC repository: NM-100, NM-101, NM-102, NM-103, NM-104 and NM-105. NM-105 was selected as principal material for the OECD test programme "Testing a representative set of manufactured nanomaterials". NM-100 is included in the series as a bulk comparator. Each of these NMs originates from one batch of commercially manufactured TiO2. The TiO2 NMs may be used as representative material in the measurement and testing with regard to hazard identification, risk and exposure assessment studies. The results for more than 15 endpoints are addressed in the present report, including physico-chemical properties, such as size and size distribution, crystallite size and electron microscopy images. Sample and test item preparation procedures are addressed. The results are based on studies by several European laboratories participating to the NANOGENOTOX Joint Action, as well as by the JRC.JRC.I.4-Nanobioscience

Techniques and Protocols for Dispersing Nanoparticle Powders in Aqueous Media—is there a Rationale for Harmonization?

Selecting appropriate ways of bringing engineered nanoparticles (ENP) into aqueous dispersion is a main obstacle for testing, and thus for understanding and evaluating, their potential adverse effects to the environment and human health. Using different methods to prepare (stock) dispersions of the same ENP may be a source of variation in the toxicity measured. Harmonization and standardization of dispersion methods applied in mammalian and ecotoxicity testing are needed to ensure a comparable data quality and to minimize test artifacts produced by modifications of ENP during the dispersion preparation process. Such harmonization and standardization will also enhance comparability among tests, labs, and studies on different types of ENP. The scope of this review was to critically discuss the essential parameters in dispersion protocols for ENP. The parameters are identified from individual scientific studies and from consensus reached in larger scale research projects and international organizations. A step-wise approach is proposed to develop tailored dispersion protocols for ecotoxicological and mammalian toxicological testing of ENP. The recommendations of this analysis may serve as a guide to researchers, companies, and regulators when selecting, developing, and evaluating the appropriateness of dispersion methods applied in mammalian and ecotoxicity testing. However, additional experimentation is needed to further document the protocol parameters and investigate to what extent different stock dispersion methods affect ecotoxicological and mammalian toxicological responses of ENP.JRC.I.4-Nanobioscience

A CASE OF A STRANGE DYSPNEA

Infantile hemangioma is the most common benign tumor of infancy, affecting 1–2% of infants. Hemangiomas of the airway constitute an even smaller percentage, but their management can be challenging due to the potential for life threatening airway compromise. A Subglottic hemangioma (SGH) makes up 1.5% of all congenital laryngeal anomalies, it is twice more common in females than males and have been linked to low birth weight and prematurity. It is during the early proliferative phase (1–3 months of life) that patients became symptomatic, developing characteristic stridor which may progress to respiratory distress. In this early stage, a SGH is often mistaken for a more common condition such as croup. The aim of this case is to underline what a recurrent dyspnea or laryngeal stridor in the first 6 months might hide Case report A 4 months-old-girl who was born at term of natural childbirth (birth weight 2.500 kg-SGA), presented with several weeks of unremitting stridor, substernal retractions. She was diagnosed to have bronchiolitis and she had been hospitalized twice in an another hospital and treated with oral steroids and nebulized racemic epinephrine without significant improvement in her symptoms; Than she had been sent to our hospital. She had intercostal and subcostal retractions. Both lungs had equal contribution to respiration, respiratory sounds were coarse and she had both inspiratory and expiratory stridors which were more obvious on bilateral sibilant rales, and inspiratory phase. She also had wheezing. Laboratory tests, echocardiogram and electrocardiogram were normal. Her follow-up showed that she was not responding to treatment and her respiratory distress was increasing, thus she had a laryngofibroscopy that did not reveal any clear structural abnormalities, and performed a CT scan of the neck, that revealed a laryngeal mass, confirmed by an MRI of the neck, which showed a solid tissues of low intensity on T1-weighted spin-echo images and of hyperintensity on T2-weighted spinecho images (6x8 mm), compatible with SGH. After her workup was complete, she received an initial dose of propranolol at 0.5 mg/kg, which was increased to 2 mg/kg, and no adverse effects were noted. SGH is a rare but potentially lifethreatening disease. A high index of suspicion is vital for the early, accurate diagnosis of this disease. Propranolol treatment has many advantages, it is non-invasive and it has a low complication rate; thus, the use of propranolol as a first-line treatment for SGH is propose